Alkem Laboratories Ltd vs Cohance Lifesciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Alkem Laboratories Ltd is ₹ 5540 as of 06 May 15:30 . The P/E Ratio of Alkem Laboratories Ltd changed from 20.9 on March 2021 to 26.9 on March 2025 . This represents a CAGR of 5.18% over 5 yearsThe P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 years The Market Cap of Alkem Laboratories Ltd changed from ₹ 33145 crore on March 2021 to ₹ 58347 crore on March 2025 . This represents a CAGR of 11.97% over 5 yearsThe Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 years The revenue of Alkem Laboratories Ltd for the Dec '25 is ₹ 3879 crore as compare to the Sep '25 revenue of ₹ 4104 crore. This represent the decline of -5.48% The revenue of Cohance Lifesciences Ltd for the Dec '25 is ₹ 550.71 crore as compare to the Sep '25 revenue of ₹ 571.17 crore. This represent the decline of -3.58% The ebitda of Alkem Laboratories Ltd for the Dec '25 is ₹ 918.31 crore as compare to the Sep '25 ebitda of ₹ 1024 crore. This represent the decline of -10.36% The ebitda of Cohance Lifesciences Ltd for the Dec '25 is ₹ 96.65 crore as compare to the Sep '25 ebitda of ₹ 136.55 crore. This represent the decline of -29.22% The net profit of Alkem Laboratories Ltd changed from ₹ 550.24 crore to ₹ 653.53 crore over 7 quarters. This represents a CAGR of 10.33% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 29.02 crore over 7 quarters. This represents a CAGR of -42.04% The Dividend Payout of Alkem Laboratories Ltd changed from 21.28 % on March 2021 to 23.59 % on March 2025 . This represents a CAGR of 2.08% over 5 yearsThe Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Alkem Laboratories Ltd

Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations.
The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. Alkem Laboratories Limited was incorporated as a private limited company on August 8, 1973 in Patna and subsequently became a deemed public limited company on October 26, 1988.
Pursuant to Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to 'Alkem Laboratories Limited' with effect from October 26, 1988.

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

FAQs for the comparison of Alkem Laboratories Ltd and Cohance Lifesciences Ltd

Which company has a larger market capitalization, Alkem Laboratories Ltd or Cohance Lifesciences Ltd?

Market cap of Alkem Laboratories Ltd is 66,239 Cr while Market cap of Cohance Lifesciences Ltd is 18,399 Cr

What are the key factors driving the stock performance of Alkem Laboratories Ltd and Cohance Lifesciences Ltd?

The stock performance of Alkem Laboratories Ltd and Cohance Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alkem Laboratories Ltd and Cohance Lifesciences Ltd?

As of May 6, 2026, the Alkem Laboratories Ltd stock price is INR ₹5540.05. On the other hand, Cohance Lifesciences Ltd stock price is INR ₹480.95.

How do dividend payouts of Alkem Laboratories Ltd and Cohance Lifesciences Ltd compare?

To compare the dividend payouts of Alkem Laboratories Ltd and Cohance Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.